Wang 2015a.

Methods	Study design: Randomised clinical trial Study duration: January 2008 to June 2011 Duration of follow‐up: 3 years Setting: Hospital
Participants	Age (mean ± SD): TACE + RFA: 52.97 ± 9.23 years; TACE alone: 51.68 ± 9.87 years Male (n/total): TACE + RFA: 36/45; TACE alone: 32/45 Child‐Pugh Class (patients): Class A: TACE + RFA: 26; TACE: 29 Class B: TACE + RFA: 19; TACE: 16
Interventions	TACE + RFA group (n = 45): TACE: Chemotherapeutic drugs: 5‐fluorouracil 1‐1.5 g, oxaliplatin 80‐100 mg, and adriamycin 10‐20 mg. In total, 3 sessions of TACE were performed, with an interval of 4 weeks. RFA: The interval between TACE and RFA was 2 weeks. Output power of 100‐150 W, 30‐60 minutes per RFA treatment TACE group (n = 45): Chemotherapeutic drugs: 5‐fluorouracil 1‐1.5 g, oxaliplatin 80‐100 mg, and adriamycin 10‐20 mg. In total, 3 sessions of TACE were performed, with an interval of 4 weeks.
Outcomes	Tumour response, according to WHO criteria, measured at 4 months after treatment Serum level of ALT, AST, TBIL, and γGT Serum level of AFP, CEA, CA‐199, and VEGF 1‐year and 3‐year survival rate
Notes	Country of study: China Source of funding: None There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.